论文部分内容阅读
免疫相关性血细胞减少症(IRH)是T淋巴细胞调控失衡、Th2细胞功能亢进,导致其下游的B淋巴细胞数量、亚群、功能异常,进而产生抗骨髓造血细胞自身抗体并破坏或抑制之,最后导致外周血细胞两系或三系的减少~([1])。目前IRH的主要治疗措施是糖皮质激素联合后续环孢素A(CsA)的免疫抑制治疗,而部分患者在足够剂量、足够血药浓度、足够疗程的治疗下,甚至使用了抗人胸腺细胞免疫球蛋白
Immune related pancytopenia (IRH) is an imbalance of T lymphocyte regulation and activation of Th2 cells leading to the number, subpopulation and dysfunction of B lymphocytes downstream thereof, thereby resulting in the destruction and inhibition of autoantibodies against bone marrow hematopoietic cells, Eventually leading to a decrease in two or three lines of peripheral blood cells ~ ([1]). At present, the main treatment of IRH is glucocorticoid combined with cyclosporin A (CsA) immunosuppressive therapy, and some patients in sufficient doses, enough blood concentration, adequate treatment of the treatment, and even the use of anti-human thymocyte immunity globulin